US-Guided Mammotome Biopsy Allows Complete Excision
November 1st 2001SEATTLE-Ultrasound (US)-guided Mammotome biopsy is both effective and safe for sampling breast lesions, Nathalie Duchesne, MD, a staff radiologist at the Hôpital du Saint-Sacrement, Quebec, said at the 101st Annual Meeting of the American Roentgen Ray Society (abstract 19). In fact, for most small lesions, the Mammotome permits complete excision of the lesion.
FDA Approves New Tests to Screen Blood for HIV and HCV
November 1st 2001ROCKVILLE, Maryland-New screening systems expected to further lower the threat of HIV and hepatitis C virus (HCV) contamination in the nation’s blood supply have received FDA approval. The agency has licensed two nucleic acid test (NAT) systems, which can significantly reduce the infection window, ie, the time in which a blood donor can be infected but the infection may not be detected. For HIV, the window with NAT is 12 days, compared with 22 days for antibody tests and 16 days for antigen tests. For HCV, the window is reduced from 82 days to 25 days.
Early Phone Follow-Up Addresses Brachytherapy Side Effects
November 1st 2001SAN DIEGO--The Cancer Center at Carle Clinic, Urbana, Illinois, has developed a phone assessment program to reach out to prostate brachytherapy patients before their 1-month follow-up visit, Mary Collins, RN, MSN, OCN, clinical nurse specialist at the Cancer Center, said at the 26th Annual Conference of the Oncology Nursing Society (abstract 73).
Memory T Cells in Bone Marrow Can Fight Tumors
November 1st 2001HEIDELBERG-A "proof of concept" study from researchers at the German Cancer Research Center shows that tumor-reactive memory T cells already present in the bone marrow of many cancer patients can be mobilized, restimulated, and deployed against the individual’s own breast, ovarian, or cervical tumor.
Digital vs Film Mammography Trial Begins
November 1st 2001BETHESDA, Maryland-The first large, multicenter study to compare digital vs standard film mammography has begun enrolling patients. The Digital Mammographic Imaging Screening Trial (DMIST) will study 49,500 women at 18 centers in the United States and one center in Canada.
Nonsurgical Prostate Cancer Treatment Yields 98% Survival Rate in Younger Men
November 1st 2001A study that evaluated 76 patients, aged 48 to 62 years, who underwent prostate brachytherapy between 1995 and 1999 using either palladium-103 or iodine-125 seed implants, reported that more than 98% achieved 5-year survival.
LHRH Analog Bone Loss Recovers 1 Year After Treatment
November 1st 2001SAN FRANCISCO-While bone mineral density decreases with ovarian ablation via the leutinizing hormone releasing hormone (LHRH) analog goserelin (Zoladex), the loss is partly recovered within a year after 2 years of treatment. Also, the loss may be minimized by the addition of tamoxifen (Nolvadex), according to an analysis of ZIPP (Zoladex in Premenopausal Patients) trial data presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 96).
Vitamin B12, Folic Acid Supplements Reduce Pemetrexed Toxicity
November 1st 2001SAN FRANCISCO-Adding vitamin B12 and folic acid to chemotherapy with pemetrexed disodium (Alimta) reduces the incidence of severe life-threatening toxicities, according to research presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO abstract 300).
Overuse Syndromes May Be an Emerging Hazard for Radiologists
November 1st 2001SEATTLE-Radiology practices that are converting to digital systems should be alert to the possibility of overuse syndromes, based on the experience of the radiology department at Tripler Army Medical Center, Honolulu. Lynne Ruess, MD, chief of pediatric radiology at Tripler, reported her department’s experience at the 101st Annual Meeting of the American Roentgen Ray Society (abstract 175).
Health-Related Quality of Life in Cancer Prevention Clinical Trials
Clinical trials of agents to prevent cancer in populations at risk are relatively recent. To date, these consist of a few large population-based studies. Trials in this area focus on the prevention of cancer in individuals with specific predetermined risk
Uncertainty in Medicine: A Talk With Dr. Djulbegovic
November 1st 2001In this article (the first of a two-part interview), Benjamin Djulbegovic, MD, PhD, discusses the uncertainty principle in clinical trials, a subject he has written about in The Lancet and elsewhere. Dr. Djulbegovic is associate professor of medicine, Divisions of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa.
Commentary (Machtay)-Anemia Treatment and the Radiation Oncologist: Optimizing Patient Outcomes
November 1st 2001Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting
Commentary (Komaki)-Anemia Treatment and the Radiation Oncologist: Optimizing Patient Outcomes
November 1st 2001Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting
Anemia Treatment and the Radiation Oncologist: Optimizing Patient Outcomes
November 1st 2001Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting
RIT Safe, Effective in Elderly and Poor-Prognosis Patients
October 10th 2001SAN FRANCISCO-Radioimmunotherapy (RIT) with the investigational radiolabeled monoclonal antibody known as Bexxar (tositumomab and iodine I-131 tositumomab) is effective and well tolerated in non-Hodgkin’s lymphoma (NHL) patients with poor prognostic features, according to retrospective analyses presented at the 37th Annual Meeting of the American Society of Clinical Oncology (ASCO).
ODAC Recommends Approval of Radiolabeled Zevalin
October 1st 2001BETHESDA, Maryland-The Oncologic Drugs Advisory Committee (ODAC) has unanimously recommended that the Food and Drug Administration approve the marketing of Zevalin (ibritumomab tiuxetan, IDEC Pharmaceuticals) for the treatment of patients with rituximab (Rituxan)-refractory follicular, B-cell non-Hodgkin’s lymphoma (NHL).
Proteomics Moves From the Laboratory to Clinical Research
October 1st 2001ROCKVILLE, Maryland-The emerging science of protein analysis called proteomics is being applied directly to the care of cancer patients in a joint research and clinical program of the Food and Drug Administration (FDA) and the National Cancer Institute (NCI). Proteomics is the study of the body’s proteins and how they function and interact.
Mental Fatigue Worries Chemotherapy Patients
October 1st 2001NEW YORK-More than 500 cancer patients across the country participated in a Cancer Care, Inc. teleconference addressing a little-discussed concern literally on the mind of many chemotherapy patients: forgetfulness during and after chemotherapy.
Patients Urged to Work With Professionals Against Fatigue
October 1st 2001NEW YORK-The persistence of fatigue for up to a year after cancer treatment is a common and debilitating occurrence. Participants in a Cancer Care, Inc. teleconference were given information on the causes of cancer-related fatigue and strategies for coping with it.
NCI Director Resigns to Head New Scientific Institute
October 1st 2001BETHESDA, Maryland-Richard D. Klausner, MD, has resigned as director of the National Cancer Institute to become president of a new scientific organization, the Case Institute for Health, Science and Technology. In a letter to President George W. Bush, Dr. Klausner called his 6-year tenure "the most challenging and rewarding of my career. The NCI is a jewel that I have had the honor to lead."
Combined PET/CT Aids in Head and Neck Cancer Management
October 1st 2001TORONTO, Canada-The combination of positron emission tomography (PET) and computed tomography (CT) has proved particularly advantageous in the diagnosis and treatment of cancer of the head and neck, Carolyn Cidis Meltzer, MD, said at the 48th Annual Meeting of the Society of Nuclear Medicine (abstract 133).
MRI Method Predicts Early Response
October 1st 2001NEW ORLEANS-Diffusion-weighted MRI reveals rapid changes in tumor water diffusion values after successful therapeutic intervention in solid tumors. It therefore appears capable of predicting treatment response within days of initiating therapy, Brian D. Ross, PhD, of the University of Michigan, said at the 92nd Annual Meeting of the American Association for Cancer Research (AACR).